<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> and <z:mp ids='MP_0003674'>oxidative stress</z:mp> play a crucial role in the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and interference with these mechanisms represents a strategy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> chemoprevention </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="40279">Allopurinol</z:chebi>, a safe molecular scavenger largely used as antigout agent, has been shown to increase survival of patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> incidence in long-term <z:hpo ids='HP_0001997'>gout</z:hpo> users in epidemiologic studies </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a randomized, double-blind, placebo-controlled preoperative trial in subjects with colorectal <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> to assess the activity of <z:chebi fb="0" ids="40279">allopurinol</z:chebi> on biomarkers of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>After complete colonoscopy and biopsy of the index <z:mpath ids='MPATH_491'>polyp</z:mpath>, 73 subjects with colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> were assigned to either placebo or one of two doses of <z:chebi fb="0" ids="40279">allopurinol</z:chebi> (100 mg or 300 mg) and treated for four weeks before <z:mpath ids='MPATH_491'>polyp</z:mpath> removal </plain></SENT>
<SENT sid="4" pm="."><plain>Change of Ki-67 labeling index in adenomatous tissue was the primary endpoint </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary endpoints were the immunohistochemical (IHC) expression of NF-κB, β-catenin, topoisomerase-II-α, and terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling (TUNEL) in <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and <z:mpath ids='MPATH_458'>normal</z:mpath> adjacent colonic tissue </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with placebo, Ki-67 levels were not significantly modulated by <z:chebi fb="0" ids="40279">allopurinol</z:chebi>, whereas β-catenin and NF-κB expression levels decreased significantly in adenomatous tissue, with a mean change from baseline of -10.6%, 95% confidence interval (CI), -20.5 to -0.7, and -8.1%, 95% CI, -22.7 to 6.5, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>NF-κB also decreased significantly in <z:mpath ids='MPATH_458'>normal</z:mpath> adjacent tissue (-16.4%; 95% CI, -29.0 to -3.8) </plain></SENT>
<SENT sid="8" pm="."><plain>No dose-response relationship was noted, except for NF-κB expression in <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="40279">Allopurinol</z:chebi> can inhibit biomarkers of oxidative activation in colon <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and <z:mpath ids='MPATH_458'>normal</z:mpath> adjacent tissue </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies should define its potential chemopreventive activity </plain></SENT>
</text></document>